Navigation Links
New findings about brain proteins suggest possible way to fight Alzheimer's
Date:10/6/2009

DALLAS Oct. 6, 2009 The action of a small protein that is a major villain in Alzheimer's disease can be counterbalanced with another brain protein, researchers at UT Southwestern Medical Center have found in an animal study.

The findings, available online in the journal Proceedings of the National Academy of Sciences, suggest a promising new tactic against the devastating illness, the researchers said.

The harmful protein, called beta-amyloid, is found in the brain and, when functioning properly, suppresses nerve activity involved with memory and learning. Its normal function can be likened to a red traffic light, restraining nerve cells from getting overexcited when they receive stimulating signals from neighboring cells. People with Alzheimer's disease, however, accumulate too much beta-amyloid the traffic light gets stuck on "red" and nerve cells become less responsive.

Another brain protein, called Reelin, acts as a "green light," stimulating nerve cells to respond more strongly to their neighbors' signals.

The new study shows that applying Reelin directly to brain slices from mice prevents excess beta-amyloid from completely silencing nerves.

"If we can identify a mechanism to keep the nerve cells functioning strongly, that might provide a way to fight Alzheimer's disease," said Dr. Joachim Herz, professor of molecular genetics and neuroscience at UT Southwestern and the study's senior author.

In the study, the researchers recorded electrical currents in the mouse hippocampus, an area of the brain associated with learning and memory. From their experiments they determined that Reelin and beta-amyloid interact with the same protein complex, called an NMDA receptor, which plays an important role in coordinating chemical signals between adjacent nerve cells.

They found that Reelin activates and strengthens the response of the NMDA receptor. In the presence of too much beta-amyloid, the receptor migrates into the cell, reducing the cell's sensitivity to incoming signals. By contrast, in strong concentrations of Reelin, the receptor remains active and the cell has the green light to continue receiving normally.

Dr. Herz said the study is especially important because this mechanism involves another protein involved in Alzheimer's called ApoE4, which is the primary risk factor for the most frequent late-onset form of the disease. The receptor that binds to ApeE molecules also binds to Reelin, and is part of the red-light/green-light complex that controls the sensitivity of the NMDA receptors.

"These results imply that Reelin, ApoE and beta-amyloid converge on the same molecular mechanism, which is critical in the Alzheimer's disease process, and Reelin may be a common factor to fight both beta-amyloid and mutated ApoE," Dr. Herz said. "This study establishes a rationale that ApoE receptors have an action that can keep the Alzheimer's disease process at bay by preventing damage in the first place."

The researchers are currently studying the role of ApoE4 in this mechanism. Mimicking or preserving normal Reelin function to stimulate the ApoE receptors might provide a path to stave off the disease, Dr. Herz said.


'/>"/>

Contact: Aline McKenzie
aline.mckenzie@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related medicine news :

1. Many Parents Share Genetic Test Findings With Kids
2. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
3. Scientists, physicians present latest findings in personalized cancer treatment and prevention
4. Health psychologists discuss latest research findings
5. Incidental findings found when radiologists take a broader look at renal MRA
6. Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings
7. The Organic Trade Association Hails Preliminary Research Findings Showing Nutritional Benefits of Organic Products
8. Key findings for all veterans seen in depression and suicide study
9. Video: BSP Pharma Inc. Announces Groundbreaking Findings from The Australian Centre for Complementary Medicine Education and Research Joint Health Clinical Study
10. 2007 Life Sciences Compensation Findings Disclosed www.compstudy.com
11. Chemoprevention, naturally: Findings on plant-derived cancer medicines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New findings about brain proteins suggest possible way to fight Alzheimer's
(Date:8/22/2017)... VEGAS, NEV. (PRWEB) , ... August 22, 2017 ... ... American Academy of Anti-Aging Medicine recently spoke at a popular international aesthetics conference ... therapy has had on restoring his patients’ health and his growing practice. , ...
(Date:8/22/2017)... ... ... past six years, Lightning Labels has sent out a call for users of its custom ... creativity of their designs. Submissions this year were open from May 18 to July 1 ... winners of the sixth annual Photo Contest, along with the prizes they've received:, ...
(Date:8/22/2017)... ... 2017 , ... Nurses at Apple Rehab Watch Hill , a nursing ... and certification in Closed Pulse Irrigation™ (CPI) for wound care. This qualifies ... Centers for Medicare and Medicaid Services, to have a CPI machine that will provide ...
(Date:8/22/2017)... ... August 22, 2017 , ... “To Walk Away”: a captivating and ... named Edward Koontz. “To Walk Away” is the creation of published author, Larry R. ... two hundred manuscripts in chemistry and religion, as well as four novels. , ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... ... heart-wrenching story of child abuse and neglect, and the struggles faced while hoping ... is the creation of published author, Judy Von Bernewitz, who spent 13 years ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... OCEANSIDE, Calif. , Aug. 15, 2017  AOTI Inc. announced ... Advanced Oxygen Therapy Inc., has recently opened a New York City ... the ever-increasing usage of its unique Topical Wound Oxygen (TWO 2 ... approved by the Accreditation Commission for Health Care (ACHC) under the ... ...
(Date:8/8/2017)... Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on ... the second quarter ended June 30, 2017. ... to date: Continued ... lead project, BL-8040: Announced plans to ... stem cell mobilization treatment for autologous bone-marrow transplantation in ...
(Date:8/7/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: DPLO ... as president, effective Aug. 7, 2017. ... pursue other interests and will serve as president emeritus during ... served us in multiple leadership roles since he joined Diplomat ... and has provided decisive, strategic leadership which continues to benefit ...
Breaking Medicine Technology: